

REACH - a non-regulatory announcement
AIM: FIPP
19 January 2026

Frontier IP Group plc
("Frontier IP" or the "Group")

Portfolio news - Strong results for TVG vaccine against zoonotic pig disease *Streptococcus suis*

Frontier IP, a specialist in commercialising intellectual property, is delighted to announce that a vaccine candidate to tackle *Streptococcus suis* ("S.suis") in pigs developed by portfolio company The Vaccine Group ("TVG" or the "Company") has outperformed a leading commercially available vaccine in challenge trials conducted by Moredun Scientific Limited ("MSL").

The results follow the outstanding success of the Company's bovine respiratory syncytial virus ("BRSV") vaccine candidates in cattle announced in November 2025. In addition to demonstrating superior performance to an existing vaccine, the results provide further strong validation for the TVG's technology because:

- they show TVG's underlying bovine herpesvirus vaccine delivery platform is highly effective in animal species other than cattle
- the bovine herpesvirus platform is able to combat different pathogens and is effective against bacterial diseases, such as S.suis, as well as viral diseases such as BRSV

The trial also showed TVG's vaccine is effective against different serotypes of the disease.

S.suis is an economically damaging pig disease that can jump to humans, causing meningitis, septicaemia and other symptoms. It is endemic in the global pig population, estimated at 780 million strong, and affects up to 60 per cent of European pig farms.

Highly respected, MSL is among the foremost Contract Research Organisations specialising in animal health and aquaculture in the UK.

TVG's vaccine evolved from a collaboration with two Chinese academic institutions and the country's Pulike Biological Engineering Company. Subsequent work was supported by further grant funding from Innovate UK. TVG has also entered a collaboration with leading Spanish animal health group Syva to develop a separate S.suis vaccine. Syva will have the option to license any vaccine developed via the collaboration.

The Company is now in talks with major animal health companies over commercial development of its BRSV vaccine candidates for use in cattle.

Jeremy Salt, TVG Chief Executive Officer, said: *"These results show how useful the BoHV-4 platform can be in delivering a wide range of efficacious vaccines for livestock. One of the key issues with control of S. suis infection is the ability to protect against multiple serotypes. In this study we have demonstrated clearly that our candidate vaccine has this ability."*

Frontier IP Chief Executive Officer Neil Crabb said: *"We are delighted by these results, which follow the outstanding success of TVG's BRSV vaccine candidates. It is now clear the technology has broad applicability across different animals and can be successful against both bacterial and viral diseases. The Company is now in good stead to find the right industry partners to bring its vaccines to market."*

ENQUIRIES

Frontier IP Group Plc

Neil Crabb, Chief Executive neil@frontierip.co.uk
Andrew Johnson, Communications and investor relations M: 07415 888 425
andrew.johnson@frontierip.co.uk
Company website: www.frontierip.co.uk

Allenby Capital Limited (Nominated Adviser) T: 0203 328 5656

Nick Athanas

The Vaccine Group Jeremy.salt@thevaccinegroup.co.uk

Jeremy Salt, CEO

ABOUT FRONTIER IP

Frontier IP unites science, finance and industry by identifying strong intellectual property and accelerating its

to further unite science, finance and industry by identifying strong intellectual property and accelerating its development through a range of commercialisation services. A critical part of the Group's work is involving relevant industry partners at an early stage of development to ensure technology meets real world demands and needs.

The Group looks to build and grow a portfolio of equity stakes and licence income by taking an active involvement in spin-out companies, including support for fund raising and collaboration with relevant industry partners at an early stage of development.

About Reach announcements

This is a Reach announcement. Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases into the public domain. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on Reach.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

NRAFLFITLFIRLIR